LIVERFASt – Simplified Brochure
Explore the essentials of LIVERFASt® with this simplified brochure. Learn how this innovative, blood-based diagnostic tool stages fibrosis, activity, and […]
Retrospective cross sectional evaluation of the LIVERFASt Test for staging liver fibrosis in MASLD patients in NIDDK studies’ populations using liver biopsy
MASLD affects more than 25% of subjects of the general population and can progress to advanced fibrosis (AF) and cirrhosis
Application of LIVERFASt Biomarkers to Evaluate Longitudinal Hepatic Fibrosis and Inflammation after HCV cure
Hepatitis C virus (HCV) infection is a common cause of both liver cirrhosis and hepatocellular carcinoma. Successful Direct antiviral agents
Comparison of the prevalence of advanced fibrosis (AF) using two combinations: Liver stiffness measurement (LSM or VCTE Fibroscan) along with LIVERSTAT (LST) or FIB-4 in a prospective chronic liver diseases (CLD) cohort
AI-based blood tests LIVERSTAT for advanced fibrosis (AF) in patients with T2D can streamline the diagnostic process. Aim of this
Combination of LIVERFASt (LF) & Liver Stiffness Measurement (LSM) using Fibroscan outperforms FIB-4 & LSM, for the identification of MASLD advanced fibrosis (AF) in patients with type 2 diabetes (T2D)
The study aims to compare retrospectively two combinations for one-step assessment of advanced fibrosis: LIVERFASt Fibrosis & Liver Stiffness Measurement
What is the Difference Between MASLD and MASH?
Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are conditions tied to the buildup of fat in
How do people get MASLD and can it be treated
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition where fat accumulates in the liver, mainly due to issues with
The Critical Link Between Metabolic Health & Liver Health
Did you know that metabolic health plays a key role in liver function? With the rise in conditions like obesity,
How common are MASLD and MASH
Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in the U.S., affecting an estimated 38% of adults. This condition
We have achieved ISO27001:2022 certification
Fibronostics is proud to announce that we have achieved ISO27001:2022 certification, another significant milestone in our company’s journey towards excellence
